Understanding 5-HT7 Modulators to Help People with Opioid Use Disorder
Official title: In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder
Funded at Praeventix, LLC · NIH-11255293 · Data updated 2026-11-12
A short study to see if targeting a serotonin receptor (5-HT7) can help reduce opioid craving and reliance in people with opioid use disorder.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Praeventix, LLC NIH-funded |
| Lab location | 1 site (Exton, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $355,190 |
| NIH project number | 1R43DA064569-01 |
| Project ID | NIH-11255293 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable for direct patient participation in this preclinical project.
✕Less likely to help
There is no direct patient participation in this rat-based study.
What this research studies
This project tests how 5-HT7 receptor modulators behave in vivo using rat models to explore potential pathways for treating opioid dependence. The findings could inform future human studies aimed at reducing cravings and improving recovery after opioid use disorder. It involves preclinical work that may pave the way for new therapies alongside existing treatments like methadone or buprenorphine. If successful, the work could lead to novel approaches that support patients in managing addiction and preventing relapse.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that help people reduce opioid cravings and support recovery.
How similar studies have gone: Prior work suggests 5-HT7 pathways influence reward and cognitive flexibility, supporting the potential for this approach; human translation remains to be tested.
Where this research is happening
-
Praeventix, LLC
Exton, United States Active
Researchers
- Principal investigator: Pippin, Douglas Anthony — Praeventix, LLC
- Study coordinator: Pippin, Douglas Anthony
Related research
Other NIH-funded projects on the same topics.
-
Systems analysis to improve opioid use disorder care after jail release (SAIA-MOUD)
A program to help people with opioid use disorder get better, faster, and safer care after they leave jail.
-
Precise epigenetic drugs for opioid addiction
A tiny, targeted drug approach is being developed to help people with opioid use disorder by rewriting the epigenetic signals in the brain to reduce cravings and relapse risk.
-
Increasing Access to Medications for Opioid Use Disorder for Unhoused Montanans
This project helps unhoused people in Montana get life-saving medicines for opioid use disorder through clinics connected to syringe service programs, a nurse-led MOUD model, and peer support.
-
Optimizing long-acting PrEP and opioid treatment for people in jails and prisons
This project tests a real-world approach to using long-acting PrEP and buprenorphine for HIV prevention and opioid treatment among incarcerated individuals and after release.
-
Scaling up medications for opioid use disorder in residential treatment programs
This grant studies how to help residential treatment programs provide medications for opioid use disorder to reduce overdoses after discharge, focusing on real-world settings and policies.
-
Increasing Capacity at a Native Community Clinic to Improve Opioid Care for urban AI/AN
This grant helps a Native American health clinic build its research capacity to better serve urban American Indian and Alaska Native people dealing with opioid use disorder and related health issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.